D-pharm inks $22M Chinese licensing pact

Israel's D-pharm has struck a $22.5 million licensing deal with a Chinese pharma company for its late-stage stroke-prevention drug. Wanbang Biopharmaceuticals will pay for the Chinese trial costs of DP-b99, which is currently in Phase III. Report